Standards for Trelegy Ellipta will be established

Administrative notice of the revised (proposal) of the MOHW's 'details on benefit criteria and methods

Five drugs, including Trelegy Ellipta, a treatment for COPD are scheduled to be registered for insurance in accordance with next month's schedule, and salary standards will be established and changed accordingly.

 

The MOHW has partially amended its notice of 'details on the criteria and methods of applying care benefits' to ensure proper insurance coverage of the drug and has entered into an inquiry.

 

The drugs that will be applied to the revision include Trelegy Ellipta, Rosuvaco Soft Cap, Rosumega Soft Cap, and Pentosin 350mg and Ultomiris, which will be registered on June 1st.

 

Among them, the drugs listed as of June 7 are likely to be partially changed following the Health Insurance Policy Committee's deliberation and resolution.

 

◆Trelegy Ellipta = COPD treatment, Trelegy Ellipta (Vilanterol trifenate + Flutisone furoate + Umeclidinium inhaler), is scheduled to be listed on the 1st of next month.

 

The MOHW has made sure that patients who are being administered with the same compound and single drugs at the same time with the drug will be paid even if they want to switch to the drug.

 

◆Omega-3-acidethylesters 90 and Rosuvaco Soft Cap = Omega-3-acidethylesters 90 and Rosuvaco Soft Cap, a complex type of dyslipidemia treatment such as Rosuvaco Soft Cap and Omega-3-acid ethyl esters 90), are scheduled to be registered as of June 1st.

 

◆Pentosin 350mg, etc.= Compound skin infections caused by Gram-positive bacteria and Pentosin 350mg, an antibiotic, are scheduled to be registered on June 7, and the standards will be established to be used as secondary drugs within the scope of permission for Daptomycin.

 

Detailed criteria for recognition should include nursing benefits if administration fails to administer Vancomycin or Teicoplanin to Staphylococcus aureus, which includes endocarditis by Meticillin-resistant strains, or if they cannot be administered due to side effects of both drugs.

 

◆Ultomiris= Adult PNH Treatment Ultomiris is scheduled to be registered on June 7, and the standards will be established by referring to the existing PNH Treatment Standards.

 

PNH in adults is a disease in which hemolysis and blood clots occur in blood vessels due to acquired abnormalities of hematopoietic stem cells and damage to organs in the body, such as kidney function abnormalities.

 

The benefit will be recognized within the scope of permission, and the patient will have to pay the full price of the medicine.

 

Because it increases sensitivity to major meningococcal infections, all patients must be given a meningococcal vaccine at least two weeks before administration, and re-vaccinated in accordance with the latest vaccination guidelines.

 

However, if the drug needs to be administered immediately, the meningococcal vaccine will be administered at the same time and antibiotics can be treated at the same time.

 

Details of the procedures, methods, and composition of the committee for the pre-approval of the drug were determined by the director of the HIRA, and matters requiring medical judgment in the pre-approval of the drug were subject to the committee's decision.

 

The MOHW has decided to confirm the revision after a review of opinions by the 25th..